When was VerAvanti founded?

VerAvanti was founded in 2012 and raised its 1st funding round 5 years after it was founded.

Where is VerAvanti located?

VerAvanti is headquartered in Redmond, United States.

How many employees does VerAvanti have?

As of Aug 31, 2026, the latest employee count at VerAvanti is 17.

Is VerAvanti a funded company?

VerAvanti is a funded company, having raised a total of $38.9M across 8 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 25, 2017.

When was the latest funding round of VerAvanti?

VerAvanti's latest funding was a $***** Grant (prize money) round on Dec 16, 2025, with participation from 1 investor.

Where does VerAvanti rank among its competitors?

VerAvanti ranks 34th amongst 629 active competitors, of which 134 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Imperative Care, which secured $100M in Mar, 2026.

Who are the top competitors of VerAvanti?

VerAvanti's top competitors include AliveCor, iRhythm Tech and Eko Health. Among them, Imperative Care secured the most recent funding round in March, 2026.

VerAvanti - 2026 Company Profile, Team, Funding & Competitors

VerAvanti is a series B company based in Redmond (United States), founded in 2012 by Gerald McMorrow. It operates as an Innovating intravascular imaging with advanced single-use endoscopes for enhanced patient care. VerAvanti has raised $38.9M in funding. The company has 629 active competitors, including 134 funded and 42 that have exited. Its top competitors include companies like AliveCor, iRhythm Tech and Eko Health.

Company Details

Innovating intravascular imaging with advanced single-use endoscopes for enhanced patient care. They are dedicated to transforming medical diagnostics and treatment through precision and innovation. Their patented Scanning Fiber Endoscope (SFE) technology aims to enhance accuracy, safety, and efficiency in intravascular procedures. The company focuses on addressing sightline gaps in cardiology, neurosurgery, and peripheral artery work, enabling more proactive diagnosis. They are developing cutting-edge solutions to improve healthcare standards, making procedures safer, faster, and more effective for both patients and providers. Their technology offers real-time, full-color visuals, enhancing diagnostic accuracy and procedural outcomes. The single-use design prioritizes patient safety by eliminating cross-contamination risks. They are advancing intravascular imaging with laser angioscopy, powered by Microelectromechanical System (MEMS), for unparalleled visualization. Their goal is to advance diagnostic precision and treatment outcomes related to intravascular care.

Website: www.veravanti.com/
Social
Phone Number: +1 **********

Key Metrics

Founded Year

2012

Location

Redmond, United States

Stage

Series B

Total Funding

$38.9M in 8 rounds

Latest Funding Round

Grant (prize money), Dec 16, 2025, $*****

Investors

HHS

Ranked

34^th among 629 active competitors

Employee Count

17 as on Aug 31, 2026

Similar Companies

iRhythm Tech & 758 more

View VerAvanti's full profile

VerAvanti has raised a total funding of $38.9M over 8 rounds. Its first funding round was on May 25, 2017. Its latest funding round was a Grant (prize money) round on Dec 16, 2025 for $*****. 1 investor participated in its latest round. VerAvanti has 1 institutional investor.

Here is the list of recent funding rounds of VerAvanti:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 16, 2025	5797612	Grant (prize money)	9300191	2338609	6199364	7425073
Oct 20, 2025	7876535	Series B	7833809	6602479	8509129	2162462
Feb 21, 2025	1758616	Series B	1049967	2481526	7566012	5360905

Access funding benchmarks and valuations. Sign up today!

View details of VerAvanti's funding rounds and investors

The founders of VerAvanti is Gerald McMorrow.

Here are the details of VerAvanti's key team members:

Gerald McMorrow: Founder and CEO of VerAvanti.
Contact Info: 1 email address

View details of VerAvanti's Founder profiles and Board Members

VerAvanti's employee count trend

VerAvanti has 17 employees as of Aug 26. Here is VerAvanti's employee count trend over the years:

Uncover VerAvanti's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of VerAvanti include AliveCor, iRhythm Tech and Eko Health. Here is the list of Top 10 competitors of VerAvanti, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AliveCor 2010, Mountain View (United States), Series F	Developer of remote cardiac monitoring solutions and related analysis software	$114M	Mayo Clinic Business Accelerator, Khosla Ventures ... & 17 others	74/100
2nd	iRhythm Tech 2006, San Francisco (United States), Public	Provider of cloud-based cardiac rhythm monitoring devices	$98.9M	UNC Kenan-Flagler Private Equity, New Leaf Venture Partners ... & 12 others	73/100
3rd	Eko Health 2013, Emeryville (United States), Series D	Manufacturer of digital stethoscopes and software for heart disease detection	$195M	Artis Ventures, EDBI & 34 others	72/100
4th	Vital Connect 2011, Campbell (United States), Acquired	Developer of biosensor patch for body vitals monitoring	$240M	MVM, Ally Bridge Group & 9 others	66/100
5th	ZOLL AEDs 1983, Chelmsford (United States), Acquired	Developer of medical devices and software solutions for emergency care	-	Nobel Investments, Military Health & 2 others	64/100
6th	Imperative Care 2015, Campbell (United States), Series E	Provider of access catheters for cardiovascular diagnosis and treatment	$596M	Ally Bridge Group, Perceptive Advisors & 21 others	64/100
7th	Welltory 2016, Redwood City (United States), Seed	Online health and wellness tracking and training platform	$1M	Braavo, Altair Capital & 6 others	63/100
8th	Biotricity 2014, San Francisco (United States), Public	Developer of medical remote monitoring solutions that help prevent and manage chronic diseases	-	SWK Holdings, National Research Council Canada ... & 2 others	62/100
9th	LUMA Vision 2017, Dublin (Ireland), Series A	Developer of interventional cardiac imaging devices	$42.3M	Life Sciences Partners, imec.xpand & 11 others	62/100
10th	Element Science 2013, San Francisco (United States), Series C	Wearable therapeutic device for treating sudden cardiac arrest	$193M	Deerfield, Qiming & 4 others	61/100
34th	VerAvanti 2012, Redmond (United States), Series B	Innovating intravascular imaging with advanced single-use endoscopes for enhanced patient care	$38.9M	HHS	48/100